NASDAQ:SYBX

Synlogic Competitors

$3.33

-0.01 (-0.30 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.27

Now: $3.33▼

$3.47

50-Day Range

$3.09

MA: $3.84▼

$4.90

52-Week Range

$1.74

Now: $3.33▼

$5.11

Volume192,351 shs

Average Volume1.07 million shs

Market Capitalization$132.06 million

P/E RatioN/A

Dividend YieldN/A

Beta2.2

Synlogic (NASDAQ:SYBX) Vs. ETNB, RAPT, FBIO, AVDL, PRVB, and NLTX

Should you be buying SYBX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Synlogic, including 89bio (ETNB), RAPT Therapeutics (RAPT), Fortress Biotech (FBIO), Avadel Pharmaceuticals (AVDL), Provention Bio (PRVB), and Neoleukin Therapeutics (NLTX).

Synlogic vs. 89bio Stock

89bio (NASDAQ:ETNB) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a breakdown of recent ratings for 89bio and Synlogic, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
89bio	0	0	6	1	3.14
Synlogic	0	1	4	0	2.80

89bio currently has a consensus target price of $62.4286, indicating a potential upside of 137.55%. Synlogic has a consensus target price of $13.25, indicating a potential upside of 297.90%. Given Synlogic's higher possible upside, analysts clearly believe Synlogic is more favorable than 89bio.

Profitability

This table compares 89bio and Synlogic's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
89bio	N/A	-49.56%	-46.52%
Synlogic	-2,761.83%	-41.64%	-34.39%

Valuation and Earnings

This table compares 89bio and Synlogic's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
89bio	N/A	N/A	$-57,420,000.00	($24.49)	-1.07
Synlogic	$2.22 million	59.49	$-51,370,000.00	($1.70)	-1.96

Synlogic has higher revenue and earnings than 89bio. Synlogic is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

80.6% of 89bio shares are held by institutional investors. Comparatively, 39.5% of Synlogic shares are held by institutional investors. 18.1% of 89bio shares are held by company insiders. Comparatively, 18.0% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Synlogic beats 89bio on 7 of the 13 factors compared between the two stocks.

Synlogic vs. RAPT Therapeutics Stock

Synlogic (NASDAQ:SYBX) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Synlogic and RAPT Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$2.22 million	59.49	$-51,370,000.00	($1.70)	-1.96
RAPT Therapeutics	N/A	N/A	$-43,000,000.00	($9.89)	-2.13

RAPT Therapeutics has lower revenue, but higher earnings than Synlogic. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and RAPT Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synlogic	-2,761.83%	-41.64%	-34.39%
RAPT Therapeutics	N/A	-48.78%	-42.35%

Analyst Ratings

This is a breakdown of recent ratings for Synlogic and RAPT Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	0	1	4	0	2.80
RAPT Therapeutics	0	0	5	0	3.00

Synlogic currently has a consensus price target of $13.25, suggesting a potential upside of 297.90%. RAPT Therapeutics has a consensus price target of $41.20, suggesting a potential upside of 95.82%. Given Synlogic's higher possible upside, analysts plainly believe Synlogic is more favorable than RAPT Therapeutics.

Institutional & Insider Ownership

39.5% of Synlogic shares are held by institutional investors. Comparatively, 65.0% of RAPT Therapeutics shares are held by institutional investors. 18.0% of Synlogic shares are held by insiders. Comparatively, 31.0% of RAPT Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Synlogic has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.

Summary

Synlogic beats RAPT Therapeutics on 7 of the 13 factors compared between the two stocks.

Synlogic vs. Fortress Biotech Stock

Synlogic (NASDAQ:SYBX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Synlogic and Fortress Biotech's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$2.22 million	59.49	$-51,370,000.00	($1.70)	-1.96
Fortress Biotech	$36.63 million	14.09	$-39,960,000.00	($0.73)	-7.45

Fortress Biotech has higher revenue and earnings than Synlogic. Fortress Biotech is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and Fortress Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synlogic	-2,761.83%	-41.64%	-34.39%
Fortress Biotech	-131.98%	-44.08%	-19.06%

Analyst Ratings

This is a breakdown of recent ratings for Synlogic and Fortress Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	0	1	4	0	2.80
Fortress Biotech	0	0	6	0	3.00

Synlogic currently has a consensus price target of $13.25, suggesting a potential upside of 297.90%. Fortress Biotech has a consensus price target of $10.75, suggesting a potential upside of 97.61%. Given Synlogic's higher possible upside, analysts plainly believe Synlogic is more favorable than Fortress Biotech.

Institutional & Insider Ownership

39.5% of Synlogic shares are held by institutional investors. Comparatively, 32.1% of Fortress Biotech shares are held by institutional investors. 18.0% of Synlogic shares are held by insiders. Comparatively, 29.5% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Synlogic has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.

Summary

Fortress Biotech beats Synlogic on 9 of the 14 factors compared between the two stocks.

Synlogic vs. Avadel Pharmaceuticals Stock

Synlogic (NASDAQ:SYBX) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Synlogic and Avadel Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$2.22 million	59.49	$-51,370,000.00	($1.70)	-1.96
Avadel Pharmaceuticals	$59.22 million	8.67	$-33,230,000.00	($0.89)	-9.87

Avadel Pharmaceuticals has higher revenue and earnings than Synlogic. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and Avadel Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synlogic	-2,761.83%	-41.64%	-34.39%
Avadel Pharmaceuticals	38.70%	-33.91%	-11.75%

Analyst Ratings

This is a breakdown of recent ratings for Synlogic and Avadel Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	0	1	4	0	2.80
Avadel Pharmaceuticals	0	0	6	0	3.00

Synlogic currently has a consensus price target of $13.25, suggesting a potential upside of 297.90%. Avadel Pharmaceuticals has a consensus price target of $18.60, suggesting a potential upside of 111.85%. Given Synlogic's higher possible upside, analysts plainly believe Synlogic is more favorable than Avadel Pharmaceuticals.

Institutional & Insider Ownership

39.5% of Synlogic shares are held by institutional investors. Comparatively, 53.8% of Avadel Pharmaceuticals shares are held by institutional investors. 18.0% of Synlogic shares are held by insiders. Comparatively, 1.4% of Avadel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Synlogic has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Summary

Avadel Pharmaceuticals beats Synlogic on 10 of the 14 factors compared between the two stocks.

Synlogic vs. Provention Bio Stock

Synlogic (NASDAQ:SYBX) and Provention Bio (NASDAQ:PRVB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.

Institutional and Insider Ownership

39.5% of Synlogic shares are held by institutional investors. Comparatively, 39.4% of Provention Bio shares are held by institutional investors. 18.0% of Synlogic shares are held by company insiders. Comparatively, 14.4% of Provention Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Synlogic and Provention Bio's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$2.22 million	59.49	$-51,370,000.00	($1.70)	-1.96
Provention Bio	N/A	N/A	$-43,280,000.00	($1.06)	-7.55

Provention Bio has lower revenue, but higher earnings than Synlogic. Provention Bio is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and Provention Bio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synlogic	-2,761.83%	-41.64%	-34.39%
Provention Bio	N/A	-67.66%	-62.27%

Risk and Volatility

Synlogic has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Provention Bio has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Synlogic and Provention Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	0	1	4	0	2.80
Provention Bio	0	1	5	0	2.83

Synlogic presently has a consensus price target of $13.25, suggesting a potential upside of 297.90%. Provention Bio has a consensus price target of $25.50, suggesting a potential upside of 218.75%. Given Synlogic's higher possible upside, equities research analysts clearly believe Synlogic is more favorable than Provention Bio.

Summary

Synlogic beats Provention Bio on 7 of the 13 factors compared between the two stocks.

Synlogic vs. Neoleukin Therapeutics Stock

Synlogic (NASDAQ:SYBX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.

Institutional and Insider Ownership

39.5% of Synlogic shares are held by institutional investors. Comparatively, 65.7% of Neoleukin Therapeutics shares are held by institutional investors. 18.0% of Synlogic shares are held by company insiders. Comparatively, 7.1% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Synlogic and Neoleukin Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$2.22 million	59.49	$-51,370,000.00	($1.70)	-1.96
Neoleukin Therapeutics	$25 million	20.27	$-69,440,000.00	($0.75)	-15.96

Synlogic has higher earnings, but lower revenue than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and Neoleukin Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synlogic	-2,761.83%	-41.64%	-34.39%
Neoleukin Therapeutics	N/A	-24.06%	-21.92%

Risk and Volatility

Synlogic has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Synlogic and Neoleukin Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	0	1	4	0	2.80
Neoleukin Therapeutics	0	0	6	0	3.00

Synlogic presently has a consensus price target of $13.25, suggesting a potential upside of 297.90%. Neoleukin Therapeutics has a consensus price target of $22.6667, suggesting a potential upside of 89.36%. Given Synlogic's higher possible upside, equities research analysts clearly believe Synlogic is more favorable than Neoleukin Therapeutics.

Summary

Neoleukin Therapeutics beats Synlogic on 8 of the 14 factors compared between the two stocks.